Your browser doesn't support javascript.
loading
Nirmatrelvir/ritonavir treatment and the risk of post-COVID condition over 180 days in Malaysia.
Low, Ee Vien; Pathmanathan, Mohan Dass; Ten, Yi Yang; Chidambaram, Suresh Kumar; Kim, Wee Ric; Lee, Wei Jia; Teh, Zhi Wei; Appannan, Maheshwara Rao; Ismail, Mastura; Samad, Azah Abdul; Peariasamy, Kalaiarasu M.
Afiliação
  • Low EV; Institute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, No.1 Jalan Setia Murni U13/52, Seksyen U13, Shah Alam, Selangor, 40170, Malaysia. evienlow@gmail.com.
  • Pathmanathan MD; Institute for Health Systems Research, National Institutes of Health, Ministry of Health Malaysia, No.1 Jalan Setia Murni U13/52, Seksyen U13, Shah Alam, Selangor, 40170, Malaysia. evienlow@gmail.com.
  • Ten YY; Institute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, No.1 Jalan Setia Murni U13/52, Seksyen U13, Shah Alam, Selangor, 40170, Malaysia.
  • Chidambaram SK; Institute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, No.1 Jalan Setia Murni U13/52, Seksyen U13, Shah Alam, Selangor, 40170, Malaysia.
  • Kim WR; Department of Medicine, Sungai Buloh Hospital, Sungai Buloh, Selangor, 47000, Malaysia.
  • Lee WJ; Digital Health Division, Ministry of Health Malaysia, Block F1, Complex F, 62000, Putrajaya, Malaysia.
  • Teh ZW; Digital Health Division, Ministry of Health Malaysia, Block F1, Complex F, 62000, Putrajaya, Malaysia.
  • Appannan MR; Digital Health Division, Ministry of Health Malaysia, Block F1, Complex F, 62000, Putrajaya, Malaysia.
  • Ismail M; Digital Health Division, Ministry of Health Malaysia, Block F1, Complex F, 62000, Putrajaya, Malaysia.
  • Samad AA; Family Health Development Division, Ministry of Health Malaysia, Block E10, Complex E, Putrajaya, 62590, Malaysia.
  • Peariasamy KM; Section 7 Health Clinic, No.2 Persiaran Kayangan, Seksyen 7, Shah Alam, Selangor, 40000, Malaysia.
BMC Infect Dis ; 24(1): 780, 2024 Aug 05.
Article em En | MEDLINE | ID: mdl-39103829
ABSTRACT

BACKGROUND:

The effect of nirmatrelvir/ritonavir on preventing post-COVID condition (PCC) in the BA4, BA5, and XBB Omicron predominant periods is not well understood. The purpose of this study was to assess how nirmatrelvir/ritonavir treatment affected both PCC and health-related quality of life.

METHODS:

This retrospective cohort study enrolled 2,524 adults aged 18 years and older who were eligible for nirmatrelvir/ritonavir between July 14 to November 14, 2022. All outcomes were observed from the patient's first visit to the primary health clinic, 1 week, 1 month, 3 months, and 6 months after testing positive for COVID-19. The primary outcome was the presence of PCC. Secondary outcomes included the effects on health-related quality of life, such as walking, bathing and dressing, activities, cause adverse emotions or signs that prevent individuals from leading normal lives over a 180-day observation period.

RESULTS:

There were no significant differences observed between the nirmatrelvir/ritonavir and those not administered (control group) in terms of PCC symptoms at 3 months (OR 0.71 95% CI 0.31, 1.64) and 6 months (OR 1.30 95% CI 0.76, 2.21). At 3 months, the use of nirmatrelvir/ritonavir was associated with a 26% reduction in symptoms causing negative emotions (OR 0.74 95% CI 0.60, 0.92) and an increased likelihood of symptoms limiting walking (OR 1.58 95% CI 1.10, 2.27). However, there were no significant differences between the nirmatrelvir/ritonavir and the control group in terms of the impact of PCC on health-related quality of life at 6 months.

CONCLUSIONS:

Our study indicates that the administration of nirmatrelvir/ritonavir does not significantly reduce PCC after 3 months and 6 months in a population with high vaccination coverage.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Ritonavir / Tratamento Farmacológico da COVID-19 Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Revista: BMC Infect Dis Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Malásia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Ritonavir / Tratamento Farmacológico da COVID-19 Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Revista: BMC Infect Dis Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Malásia